ArticleJournal of inflammation research2025
A Case Report of Wolf's Post-Herpetic Isotopic Response: Herpetiform Pemphigus.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a rare case of Wolf's post-herpetic isotopic response (PHIR) manifesting as herpetiform pemphigus (HP) after herpes zoster (HZ) infection and explore its potential pathogenesis. Patients and Methods: A 76-year-old male patient with a history of HZ on the right lateral waist, abdomen, and back. Fifteen days after the cure of HZ, annular erythema, blisters, and pruritus appeared at the original site of the same skin lesions and then spread throughout the body. Retrospective analysis was performed through clinical examination, histopathology, direct immunofluorescence, and autoantibody detection. Results: The patient was diagnosed with PHIR presenting as HP based on medical history and test results. Treatment with methylprednisolone (initial dose 40 mg/day) and antibiotics resolved lesions within 2 weeks, with no recurrence during 18 months of follow-up. The pathogenesis was hypothesized to involve local and systemic immune microenvironment changes induced by varicella-zoster virus (VZV) infection. Conclusion: HP developing after HZ may represent a novel manifestation of PHIR, providing new evidence for this phenomenon. Clinicians should consider immune-related bullous diseases in post-HZ skin lesions. Larger studies are needed to validate the association between viral infection and immune imbalance in pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.